Henry Schein (NASDAQ:HSIC - Get Free Report) had its target price increased by research analysts at Morgan Stanley from $64.00 to $68.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has an "underweight" rating on the stock. Morgan Stanley's target price would indicate a potential downside of 19.96% from the stock's previous close.
A number of other equities analysts also recently issued reports on HSIC. UBS Group raised their price objective on Henry Schein from $94.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 4th. Barrington Research set a $104.00 target price on Henry Schein in a report on Wednesday, August 5th. Wall Street Zen upgraded Henry Schein from a "hold" rating to a "buy" rating in a report on Monday, August 17th. Citigroup reissued a "buy" rating and set a $112.00 target price (up from $100.00) on shares of Henry Schein in a research report on Wednesday, August 5th. Finally, Barclays restated an "overweight" rating and set a $100.00 price target (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $93.86.
Check Out Our Latest Research Report on Henry Schein
Henry Schein Stock Performance
Shares of Henry Schein stock opened at $84.96 on Tuesday. The stock has a market cap of $9.39 billion, a price-to-earnings ratio of 23.28, a P/E/G ratio of 1.51 and a beta of 0.87. Henry Schein has a twelve month low of $68.70 and a twelve month high of $92.18. The company's fifty day moving average is $85.81 and its 200 day moving average is $81.59. The company has a quick ratio of 0.76, a current ratio of 1.33 and a debt-to-equity ratio of 0.62.
Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.20. Henry Schein had a return on equity of 16.39% and a net margin of 3.07%. The business had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period last year, the company earned $1.38 EPS. Henry Schein's revenue for the quarter was up 4.0% compared to the same quarter last year. Sell-side analysts forecast that Henry Schein will post 5.55 EPS for the current year.
Institutional Trading of Henry Schein
A number of large investors have recently bought and sold shares of the business. Southpoint Capital Advisors LP increased its position in shares of Henry Schein by 28.0% during the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company's stock valued at $235,840,000 after acquiring an additional 700,000 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Henry Schein during the second quarter worth $42,261,000. Defilade Capital Management L.P. lifted its holdings in Henry Schein by 94.8% during the first quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company's stock worth $45,992,000 after acquiring an additional 303,615 shares during the period. Bank of Nova Scotia boosted its position in Henry Schein by 1,263.1% in the first quarter. Bank of Nova Scotia now owns 116,808 shares of the company's stock worth $8,609,000 after purchasing an additional 108,239 shares during the last quarter. Finally, Banyan Capital Management Inc. purchased a new position in Henry Schein in the third quarter worth $8,023,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Henry Schein
Here are a few of the latest headlines about HSIC:
Henry Schein Company Profile
(
Get Free Report)
Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.